A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management.

ABSTRACT:

Objectives

The 21-gene assay Oncotype DX (21-GA) shows promise as a guide in deciding when to initiate adjuvant chemotherapy in women with hormone receptor-positive early-stage breast cancer. Nevertheless, its routine use remains controversial, owing to insufficient evidence of its clinical utility and cost-effectiveness. Accordingly, we aim to quantify the value of conducting further research to reduce decision uncertainty in the use of the 21-GA.

Methods

Using value of information methods, we first generated probability distributions of survival and costs for decision making with and without the 21-GA alongside traditional risk prediction. These served as the input to a comparison of 3 alternative study designs: a retrospective observational study to update risk classifica

SUBMITTER: Kunst NR 

PROVIDER: S-EPMC7343670 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature